Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells
Authors
Keywords
-
Journal
Mucosal Immunology
Volume 7, Issue 4, Pages 842-856
Publisher
Springer Nature
Online
2013-11-27
DOI
10.1038/mi.2013.101
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model
- (2013) Stefanie Kirchberger et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Identification of a genetic locus controlling bacteria-driven colitis and associated cancer through effects on innate inflammation
- (2012) Olivier Boulard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells
- (2012) Jonathan P Sherlock et al. NATURE MEDICINE
- Smad4 deficiency in T cells leads to the Th17-associated development of premalignant gastroduodenal lesions in mice
- (2011) Jennifer Nancy Hahn et al. JOURNAL OF CLINICAL INVESTIGATION
- IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease
- (2011) Alessandra Geremia et al. JOURNAL OF EXPERIMENTAL MEDICINE
- IL-23 Is Critical for Induction of Arthritis, Osteoclast Formation, and Maintenance of Bone Mass
- (2011) I. E. Adamopoulos et al. JOURNAL OF IMMUNOLOGY
- Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice
- (2011) J H Cox et al. Mucosal Immunology
- Risk of Extra-Intestinal Cancer in Inflammatory Bowel Disease: Meta-Analysis of Population-Based Cohort Studies
- (2010) Natalia Pedersen et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Immunity, Inflammation, and Cancer
- (2010) Sergei I. Grivennikov et al. CELL
- Inflammation and Colon Cancer
- (2010) Janoš Terzić et al. GASTROENTEROLOGY
- Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease
- (2010) Reiko M. Onishi et al. IMMUNOLOGY
- Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology
- (2010) Sofia Buonocore et al. NATURE
- IL-12 initiates tumor rejection via lymphoid tissue–inducer cells bearing the natural cytotoxicity receptor NKp46
- (2010) Maya Eisenring et al. NATURE IMMUNOLOGY
- IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer
- (2009) Sergei Grivennikov et al. CANCER CELL
- Cutting Edge: IL-23 Receptor GFP Reporter Mice Reveal Distinct Populations of IL-17-Producing Cells
- (2009) Amit Awasthi et al. JOURNAL OF IMMUNOLOGY
- A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses
- (2009) Shaoguang Wu et al. NATURE MEDICINE
- Macrophage-derived IL-1β stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3
- (2009) P Kaler et al. ONCOGENE
- Overexpression of Interleukin-1β Induces Gastric Inflammation and Cancer and Mobilizes Myeloid-Derived Suppressor Cells in Mice
- (2008) Shuiping Tu et al. CANCER CELL
- IL-23 and Th17 cytokines in intestinal homeostasis
- (2008) K J Maloy et al. Mucosal Immunology
- Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens
- (2008) Yan Zheng et al. NATURE MEDICINE
- Cytokine-based transformation of immune surveillance into tumor-promoting inflammation
- (2008) J B Mumm et al. ONCOGENE
- Cancer in inflammatory bowel disease
- (2008) Jianlin Xie et al. WORLD JOURNAL OF GASTROENTEROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More